• DOI:10.1056/NEJMoa1112072
• Corpus ID: 33597901

Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

@article{vanVollenhoven2012TofacitinibOA,
  title={Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.},
  author={Ronald F. van Vollenhoven and Roy M. Fleischmann and Stanley B. Cohen and Eun Bong Lee and Juan A Garc{\'i}a Meijide and Sylke Wagner and {\vS}{\'a}rka Forejtov{\'a} and Samuel H. Zwillich and David Gruben and Tam{\'a}s Koncz and Gene Wallenstein and Sriram Krishnaswami and John D. Bradley and Bethanie E Wilkinson},
  journal={The New England journal of medicine},
  year={2012},
  volume={367 6},
  pages={
          508-19
        }
}

• R. V. van Vollenhoven, R. Fleischmann, +11 authors B. Wilkinson
• Published 8 August 2012
• Medicine, Psychology
• The New England journal of medicine

BACKGROUND
Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being investigated for the treatment of rheumatoid arthritis.

METHODS
In this 12-month, phase 3 trial, 717 patients who were receiving stable doses of methotrexate were randomly assigned to 5 mg of tofacitinib twice daily, 10 mg of tofacitinib twice daily, 40 mg of adalimumab once every 2 weeks, or placebo. At month 3, patients in the placebo group who did not have a 20% reduction from baseline in the number of swollen and tender joints were switched in a blinded fashion to either 5 mg or 10 mg of tofacitinib twice daily; at month 6, all patients still receiving placebo were switched to tofacitinib in a blinded fashion. The three primary outcome measures were a 20% improvement at month 6 in the American College of Rheumatology scale (ACR 20); the change from baseline to month 3 in the score on the Health Assessment Questionnaire-Disability Index (HAQ-DI) (which ranges from 0 to 3, with higher scores indicating greater disability); and the percentage of patients at month 6 who had a Disease Activity Score for 28-joint counts based on the erythrocyte sedimentation rate (DAS28-4[ESR]) of less than 2.6 (with scores ranging from 0 to 9.4 and higher scores indicating greater disease activity).

RESULTS
At month 6, ACR 20 response rates were higher among patients receiving 5 mg or 10 mg of tofacitinib (51.5% and 52.6%, respectively) and among those receiving adalimumab (47.2%) than among those receiving placebo (28.3%) (P<0.001 for all comparisons). There were also greater reductions in the HAQ-DI score at month 3 and higher percentages of patients with a DAS28-4(ESR) below 2.6 at month 6 in the active-treatment groups than in the placebo group. Adverse events occurred more frequently with tofacitinib than with placebo, and pulmonary tuberculosis developed in two patients in the 10-mg tofacitinib group. Tofacitinib was associated with an increase in both low-density and high-density lipoprotein cholesterol levels and with reductions in neutrophil counts.

CONCLUSIONS
In patients with rheumatoid arthritis receiving background methotrexate, tofacitinib was significantly superior to placebo and was numerically similar to adalimumab in efficacy. (Funded by Pfizer; ORAL Standard ClinicalTrials.gov number, NCT00853385.).